EQL Pharma AB (publ) (FRA:7JK)
Germany flag Germany · Delayed Price · Currency is EUR
5.49
+0.11 (2.04%)
Last updated: Jan 23, 2026, 9:55 AM CET

EQL Pharma AB Cash Flow Statement

Millions SEK. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Net Income
29.6143.1222.7130.9231.5510.37
Depreciation & Amortization
10.110.17.667.432.76-
Other Amortization
2.422.420.621.140.78-
Asset Writedown & Restructuring Costs
--0.477.846.73-
Other Operating Activities
14.4211.230.078.137.218.41
Change in Accounts Receivable
-36.88-67.15-14.25-16.86-11.69-6.27
Change in Inventory
-58.87-73.41-40.26-23.690.68-14
Change in Other Net Operating Assets
31.0249.0411.5412.723.8351.54
Operating Cash Flow
-8.18-24.65-11.4427.6241.8360.05
Operating Cash Flow Growth
----33.98%-30.34%797.97%
Capital Expenditures
-11.01-6.13-0.93-0.46-0.63-0.41
Sale (Purchase) of Intangibles
-254.36-239.72-65.34-20.05-21.46-55.17
Other Investing Activities
--0--0--
Investing Cash Flow
-265.37-245.84-66.26-20.51-22.09-55.58
Long-Term Debt Issued
-357.9453.97-0.612.88
Long-Term Debt Repaid
--25.71-0.49-4.07-6.58-1.08
Net Debt Issued (Repaid)
307.49332.2353.48-4.07-5.9811.8
Issuance of Common Stock
32.490.190.270.190.86-
Other Financing Activities
---0--
Financing Cash Flow
339.98332.4353.74-3.88-5.1211.8
Miscellaneous Cash Flow Adjustments
---0---
Net Cash Flow
66.4361.93-23.963.2314.6216.27
Free Cash Flow
-19.19-30.78-12.3627.1641.259.64
Free Cash Flow Growth
----34.08%-30.92%864.27%
Free Cash Flow Margin
-4.81%-8.24%-4.68%10.45%10.05%33.29%
Free Cash Flow Per Share
-0.63-1.03-0.410.921.422.05
Cash Interest Paid
24.5213.024.012.292.78-
Cash Income Tax Paid
-----0.06
Levered Free Cash Flow
-290.39-291.16-89.53-9.91.84-60.68
Unlevered Free Cash Flow
-275.48-283.45-85.95-8.423.64-59.99
Change in Working Capital
-64.74-91.52-42.96-27.83-7.1831.27
Source: S&P Global Market Intelligence. Standard template. Financial Sources.